Pemazyre 13.5 mg (Pemigatinib TABLET) 13.5 MG

PEMAZYRE 13.5 MG tablets contain pemigatinib, a medication used to treat certain conditions. Learn about its uses, effects, and precautions here.

Strength

13.5 MG

Manufacturer / TM Owner

INCYTE CORPORATION

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

PEMAZYRE 13.5 MG tablets are primarily used for targeted therapy in specific medical conditions. Pemigatinib, the active ingredient, is often prescribed for conditions related to abnormal cell growth. Patients may wonder, 'What is PEMAZYRE used for?' This medication is designed to interact with specific receptors to help manage these conditions.

Side Effects

Common effects of PEMAZYRE 13.5 MG tablets may include gastrointestinal discomfort, fatigue, and changes in hair or skin. Some users might experience mild to moderate reactions, but these effects vary widely among individuals. Always consult a healthcare provider for personalized advice.

Precautions & Warnings

Handling PEMAZYRE 13.5 MG tablets requires careful consideration of individual health profiles. It is important to follow the guidance of a healthcare professional regarding administration and monitoring. Store the medication as directed to maintain its efficacy and safety.

Avoid Interactions

PEMAZYRE 13.5 MG tablets may interact with certain medications, including those metabolized by specific liver enzymes. Alcohol and other substances can also affect how this medication works. Always inform your healthcare provider about all medications and supplements you are taking.

Frequently Asked Questions

PEMAZYRE 13.5 MG tablets are used for targeted therapy in specific medical conditions related to abnormal cell growth.

Store PEMAZYRE 13.5 MG tablets at room temperature, away from moisture and heat, as directed by your healthcare provider.

Common effects may include gastrointestinal discomfort, fatigue, and changes in hair or skin, but these can vary among individuals.

PEMAZYRE may interact with certain medications, so always consult your healthcare provider before combining it with other treatments.

PEMAZYRE is available in a 13.5 MG strength, but other strengths may be available depending on the manufacturer and region.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.